Ballentine Partners LLC Buys 4,130 Shares of Haleon plc (NYSE:HLN)

Ballentine Partners LLC grew its position in Haleon plc (NYSE:HLN) by 18.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 26,961 shares of the company’s stock after acquiring an additional 4,130 shares during the quarter. Ballentine Partners LLC’s holdings in Haleon were worth $257,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in HLN. Rhumbline Advisers raised its position in Haleon by 20.0% in the 2nd quarter. Rhumbline Advisers now owns 48,966 shares of the company’s stock worth $404,000 after purchasing an additional 8,160 shares during the period. Dimensional Fund Advisors LP grew its stake in shares of Haleon by 2.5% during the second quarter. Dimensional Fund Advisors LP now owns 1,007,458 shares of the company’s stock valued at $8,322,000 after buying an additional 24,673 shares during the last quarter. Blair William & Co. IL grew its stake in shares of Haleon by 21.0% during the second quarter. Blair William & Co. IL now owns 40,449 shares of the company’s stock valued at $334,000 after buying an additional 7,020 shares during the last quarter. Hsbc Holdings PLC raised its holdings in shares of Haleon by 132.6% in the second quarter. Hsbc Holdings PLC now owns 35,876 shares of the company’s stock worth $296,000 after buying an additional 20,449 shares during the period. Finally, AE Wealth Management LLC lifted its stake in shares of Haleon by 6.1% during the 2nd quarter. AE Wealth Management LLC now owns 19,199 shares of the company’s stock worth $159,000 after acquiring an additional 1,098 shares during the last quarter. Institutional investors own 6.67% of the company’s stock.

Wall Street Analyst Weigh In

HLN has been the topic of a number of recent analyst reports. Morgan Stanley lowered Haleon from an “overweight” rating to an “equal weight” rating in a research note on Friday, January 10th. UBS Group raised shares of Haleon to a “strong-buy” rating in a research note on Tuesday, October 1st. Finally, Sanford C. Bernstein cut shares of Haleon from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 8th. Three research analysts have rated the stock with a hold rating, three have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $10.95.

Haleon Price Performance

HLN opened at $9.40 on Friday. The company has a market capitalization of $42.53 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 2.60 and a beta of 0.29. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. Haleon plc has a 12-month low of $7.89 and a 12-month high of $10.80. The business’s fifty day simple moving average is $9.54 and its 200-day simple moving average is $9.72.

Haleon (NYSE:HLN) last issued its earnings results on Thursday, October 31st. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. Haleon had a net margin of 10.85% and a return on equity of 14.76%. The company had revenue of $3.62 billion for the quarter, compared to analysts’ expectations of $3.74 billion. During the same period in the prior year, the business earned $0.10 EPS. On average, equities research analysts anticipate that Haleon plc will post 0.44 earnings per share for the current fiscal year.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.